Evidence map›Paper›PMID 22155153›Full record

ArticleMatrix biology : journal of the International Society for Matrix Biology2012

Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration.

Stephen P Evanko, Susan Potter-Perigo, Paul L Bollyky, Gerald T Nepom, Thomas N Wight

Abstract read
In one paragraph

Article in Matrix biology : journal of the International Society for Matrix Biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 155 citations in OpenAlex.

  1. Oral hymecromone decreases hyaluronan in human study participants.The Journal of clinical investigation · 2022
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution.

Stephen P EvankoBenaroya Research Institute, Seattle, WA 98101, United States.
Susan Potter-Perigo
Paul L Bollyky
Gerald T Nepom
Thomas N Wight
Benaroya Research Institute

Funding

VLA-4 and VCAM-1 in Advanced AtherosclerosisP01HL018645 · NHLBI · UNIVERSITY OF WASHINGTON · PI HARLAN, JOHN MARSHALL · 1985 to 2010
$23.9M
SUSCEPTIBILITY GENES IN TYPE I DIABETESR01DK046635 · NIDDK · UNIVERSITY OF VIRGINIA · PI CONCANNON, PATRICK · 1993 to 2013
$5.4M
Tissue Cytokine Sequestration and Immune Regulation in AutoimmunityU01AI101984 · NIAID · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2021
$5.0M
Lymph Node Extracellular Matrix in Antigen Presentation and Immune RegulationR01DK096087 · NIDDK · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2021
$3.4M
HLA SUSCEPTIBILITY GENES IN RHEUMATOID ARTHRITIS (RA)R01AR037296 · NIAMS · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI NEPOM, GERALD T · 1986 to 2009
$2.9M
ECM Costimulation of Immunoregulatory Pathways in Airway InflammationR01HL113294 · NHLBI · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2016
$2.0M
Extracellular matrix and the regulation of adaptive immune responsesK08DK080178 · NIDDK · UNIVERSITY OF WASHINGTON · PI BOLLYKY, PAUL L · 2007 to 2011
$702k
Extracellular matrix and the regulation of adaptive immune responsesR03DK089128 · NIDDK · UNIVERSITY OF WASHINGTON · PI BOLLYKY, PAUL L · 2010 to 2011
$155k
NHLBI NIH HHS HL018645NHLBI NIH HHS P01 HL018645NHLBI NIH HHS R01 HL113294NIAID NIH HHS U01 AI101984NIAMS NIH HHS AR037296NIAMS NIH HHS R01 AR037296NIDDK NIH HHS DK046635NIDDK NIH HHS DK080178NIDDK NIH HHS DK089128NIDDK NIH HHS K08 DK080178NIDDK NIH HHS R01 DK046635NIDDK NIH HHS R01 DK096087NIDDK NIH HHS R03 DK089128
6 · The paper itself

Abstract

The ability of lymphocytes to migrate freely through connective tissues is vital to efficient immune function. How the extracellular matrix (ECM) may affect T-cell adhesion and migration is not well understood. We have examined the adhesion and migration of activated human T-lymphocytes on ECM made by fibroblast-like synoviocytes and lung fibroblasts. These cells were minimally interactive until treated with a viral mimetic, Poly I:C. This treatment promoted myofibroblast formation and engendered a higher-order structured ECM, rich in versican and hyaluronan, to which T-cells avidly adhered in a hyaluronidase-sensitive manner. This Poly I:C-induced matrix impeded T-cell spreading and migration on and through synoviocyte monolayers, while hyaluronidase treatment or adding versican antibody during matrix formation reversed the effect on T-cell migration. Hyaluronidase also reversed the spread myofibroblast morphology. These data suggest that the viscous hyaluronan- and versican-rich matrix binds and constrains T-lymphocytes. Using purified matrix components and solid state matrices of defined composition, we uncovered a role for versican in modulating hyaluronan-T-cell interactions. Versican prevented T-cell binding to soluble hyaluronan, as well as the amoeboid shape change on hyaluronan-coated dishes and T-cell penetration of collagen gels. Together, these data suggest that hyaluronan and versican play a role in T-cell trafficking and function in inflamed tissues.

Indexed as

Cell MovementCD4-Positive T-LymphocytesCell AdhesionCells, CulturedCollagenExtracellular MatrixFibroblastsFluorescein-5-isothiocyanateHumansHyaluronan ReceptorsHyaluronic AcidHyaluronoglucosaminidaseInflammationLungLymphocyte ActivationPoly I-CCD44 protein, humanCollagenFluorescein-5-isothiocyanateHyaluronan ReceptorsHyaluronic AcidHyaluronoglucosaminidasePoly I-CVCAN protein, humanVersicans

Identifiers

PMID22155153
PMCPMC3288568
OpenAlexW2007052191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.